Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)
This study is designed to watch and understand how a treatment called Dupixent works for people with a type of eczema called atopic dermatitis. It's not a typical trial with new medicines, but rather an observation of how Dupixent is used in real life, after a doctor has already prescribed it for a patient. Researchers will collect information on patients' health history, how they use Dupixent, how effective it is over time, and any other allergic conditions they might have. They will also look at any side effects. This helps us understand the long-term benefits and safety of Dupixent when used by people aged 12 and older in their daily lives.
At a glance
What is this study about?
This study is about a medicine called Dupixent, which is used to treat a type of eczema known as atopic dermatitis. Instead of testing a new drug, this study aims to learn about Dupixent's use in real life, after it has been prescribed by a doctor as part of your normal care. Think of it like a long-term survey, where researchers gather information from people who are already starting Dupixent treatment.
The main goals are to understand who uses Dupixent, how they use it (like how often or for how long), and how well it helps with their eczema over time. Researchers will also look at how Dupixent might affect other allergic conditions you might have, such as asthma or hay fever, and keep an eye on any side effects that might pop up during the treatment.
By collecting this information, doctors and researchers can get a clearer picture of how Dupixent works for a wide range of patients outside of strict clinical trial settings. This helps healthcare professionals and patients make more informed decisions about treating atopic dermatitis.
Key takeaways
- This is an observation study, not a drug trial.
- It helps us learn about Dupixent's long-term effects in real-world use.
- You must be 12 years or older and newly starting Dupixent for eczema.
- Participation involves sharing information about your health and treatment.
- It aims to understand both effectiveness and safety over time.
- You can stop participating at any point.
Who may be eligible?
You might be able to take part if you are 12 years old or older and are just starting treatment with Dupixent for your eczema (atopic dermatitis). You need to be willing to follow the study's instructions and fill out questionnaires about your health and treatment.
However, you won't be able to join if your doctor thinks you have a medical condition that would make it hard for you to take part fully, like a very short life expectancy or severe memory problems. Also, if you've used Dupixent in the last six months, you wouldn't be able to join this particular study. Only your doctor can tell you for sure if you meet all the requirements.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 12 years old or older?
- Are you just about to start Dupixent for your eczema?
- Can you understand and fill out questionnaires?
- Are you willing and able to attend study visits?
- Have you NOT used Dupixent in the last six months?
What does participation involve?
If you decide to take part, you will be observed as you receive Dupixent as prescribed by your doctor – it's not given as part of the study. You will have regular visits where researchers will record information about your health, how your eczema is doing, and how you're using Dupixent. You will also be asked to fill out questionnaires about your symptoms and experiences. The study aims to follow you over a long period to understand the long-term effects of Dupixent.
Potential risks and benefits
Locations (99)
- Regeneron Investigational SiteVerified postcodeBirmingham, United States
- Regeneron Investigational SiteVerified postcodeGilbert, United States
- Regeneron Investigational SiteVerified postcodeFountain Valley, United States
- Regeneron Investigational SiteVerified postcodeLaguna Hills, United States
- Regeneron Investigational SiteVerified postcodeLoma Linda, United States
- Regeneron Investigational SiteVerified postcodeLos Angeles, United States
- Regeneron Investigational SiteVerified postcodeLos Angeles, United States
- Regeneron Investigational SiteVerified postcodeManhattan Beach, United States
- Regeneron Investigational SiteVerified postcodeNewport Beach, United States
- Regeneron Investigational SiteVerified postcodeOceanside, United States
- Regeneron Investigational SiteVerified postcodeRedondo Beach, United States
- Regeneron Investigational SiteVerified postcodeRiverside, United States
Common questions
What is the main purpose of this study?
The study aims to understand how Dupixent works for people with eczema in their daily lives, including how it's used, how effective it is, and any side effects over time.
Will I be given Dupixent as part of this study?
No, you will only be included if your doctor has already prescribed Dupixent for your eczema as part of your standard medical care, and you are just starting it.
Who can take part in this study?
You must be 12 years or older, starting Dupixent for eczema, and able to follow study instructions and complete questionnaires.
What will I need to do if I join?
You'll have your information collected at regular visits and fill out questionnaires about your health and Dupixent treatment. This will happen over a long period.
Can I stop being part of the study if I change my mind?
Yes, you can leave the study at any time, and it won't affect the medical care you receive from your doctor.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.